Editas Medicine (EDIT) Amortizatization of Intangibles (2022 - 2025)
Editas Medicine (EDIT) reported Amortizatization of Intangibles of $62000.0 for Q3 2025, down 95.32% year-over-year from $1.3 million in Q3 2024, and down 75.88% on a QoQ basis from $257000.0 in Q2 2025.
Editas Medicine (EDIT) has 4 years of Amortizatization of Intangibles data on file, last reported at $62000.0 in Q3 2025.
- Quarterly Amortizatization of Intangibles fell 95.32% year-over-year to $62000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.8 million (down 74.79% YoY) and the FY2024 annual result came in at $5.8 million, up 20.07% from the prior year.
- Amortizatization of Intangibles slipped to $62000.0 in Q3 2025 per EDIT's latest filing, from $257000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.1 million in Q4 2023 and bottomed at $62000.0 in Q3 2025.
- The 4-year median for Amortizatization of Intangibles is $824500.0 (2023), against an average of $1.0 million.
- The widest annual swing landed in 2023, when Amortizatization of Intangibles surged 322.29%; it then plunged 95.32% in 2025.
- Tracing EDIT's Amortizatization of Intangibles over 4 years: stood at $498000.0 in 2022, then surged by 322.29% to $2.1 million in 2023, then plunged by 58.68% to $869000.0 in 2024, then sank by 92.87% to $62000.0 in 2025.
- Per Business Quant, the three latest EDIT Amortizatization of Intangibles figures stand at $62000.0 (Q3 2025), $257000.0 (Q2 2025), and $583000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 62,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Mar 31, 2025 | 583,000.00 |
| Mar 31, 2025 | 583,000.00 |
| Dec 31, 2024 | 869,000.00 |
| Dec 31, 2024 | 869,000.00 |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 780,000.00 |
| Jun 30, 2023 | 780,000.00 |
| Mar 31, 2023 | 693,000.00 |
| Mar 31, 2023 | 693,000.00 |
| Dec 31, 2022 | 498,000.00 |
| Dec 31, 2022 | 498,000.00 |